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Abstract
Background There are noticeable gaps in knowledge regarding the cost and effectiveness of integrated medical and behavioral services for older adults with HIV. Their lifespan is close to the population’s level but their quality of life has sharply
declined due to depression and substance use. Mental health disorders are widespread among an aging population with HIV.
Objective The aim of this study was to build a decision analytic model to evaluate medical interventions with and without
mental health treatment using primary data of 139 older adults with HIV and health outcomes from the literature.
Methods We tracked the progression of depression and cumulative deaths among older adults with HIV using a Markov
model with 50 annual cycles through three health states. Deterministic and probabilistic sensitivity analyses addressed
uncertainty in estimating the parameters and around the model’s assumptions.
Results An integrated medical and behavioral care system is cost effective at a willingness to pay of $50,000 per QALY
compared with medical care only. The incremental cost was $516,452 and the incremental effectiveness was 38.8 qualityadjusted life-years (QALY), with an incremental cost-effectiveness ratio of $13,316 per QALY.
Conclusions Appropriate and efficacious referrals to integrated medical + behavioral services, either in the same facility
or connected to their primary care doctor, are instrumental to reverse loses in quality of life and avoid premature death. If
mental health is left unattended, HIV would progress, causing declines in quality of life and ultimately triggering premature
death. Reliable data on the cost and effectiveness of different types of HIV integrated services are needed.
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Mental health disorders reduce quality of life and accelerate premature death among older adults with HIV.
A medical + behavioral strategy is cost effective, with
an incremental cost-effectiveness ratio of $13,316 per
quality-adjusted life-year.
More evidence-based data on treatment cost and effectiveness is needed to assess the benefits of mental health
interventions.

1 Introduction
The economics of HIV, aging, and mental health have
received poor attention in the literature. HIV is a complex medical challenge as well as an economic and public
health issue. The effect of aging on HIV and whether HIV
resulted in increased mortality and shortened life expectancy
Vol.:(0123456789)
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is controversial [1]. The well-being of older adults with
HIV (OAWH), i.e. individuals 50 years of age and older,
is adversely affected by low antiretroviral therapy (ART)
adherence, substance use, depression, social isolation, and
loneliness. These behavioral disorders cause a decline in
quality of life (QoL) and premature death among OAWH
compared with other groups [2]. ART has sharply expanded
life expectancy for people with HIV [3, 4] but their QoL has
worsened due to ART toxicity, aging, comorbidities, polypharmacy, and mental health disorders [5–9]. At most, 50%
of people with HIV under ART suffer from HIV-associated
neurocognitive disorders (HAND), such as HIV-associated
dementia, and mild neurocognitive disorders defined as
lower performance in neurocognitive tests [10–12]. Depression is a chronic and recurrent disease, seldom identified
as a factor affecting the outcome of treatment. Episodes of
depression increase their frequency over time and their duration is consistent within people with gradual changes over
time [13]. Untreated behavioral illnesses are associated with
individuals’ perception of need for care or to social-structural barriers [14]. Those already linked to HIV treatment
can benefit from easy access to suitable mental health care,
ranging from costly clinical interventions for severe depression to low-cost options through trained health care workers
or group therapy.
A reasonable question is whether achieving lower depression levels with analogous increases in QoL for moderately
or severely depressed OAWH is cost effective. Treating
people with mild depression reduces the risk of developing
major depression over time; thus, addressing depression and
substance use is key in reducing the HIV burden [15–17].
Depression is related to low QoL and high medical costs, but
psychological interventions can reduce depressive episodes
substantially [18]. There is evidence of the benefits of social
interaction and engagement on the health and well-being
among older adults in successful aging [19]; better care is
positively associated with higher survival rates among HIVinfected individuals but is suboptimal when patients have
mental health disorders and are substance users [20]. Behavioral care can be grouped as “pharmacotherapy, psychological therapy and the combination of the two” [21]. Some programs are seemingly low-cost, involving weekly phone calls
to OAWH from case managers to identify needed resources,
but others such as cognitive behavioral therapy are provided
at moderate cost [22–24]. Early interventions are advantageous because HIV progression can be triggered if mental
health disorders are left unattended [25]. There is narrow
evidence on the cost effectiveness regarding outcomes for
patients and the delivery of service when combining HIV
care and mental health services in different settings [26].
HIV medical care integrated with depression and substance
use treatment could be cost saving and cost effective if it
identifies specific needs for care [27–29]. Integrated systems

are cost effective if mental health is provided in HIV clinics [30]; suitably combining group support psychological
treatment with HIV care is cost effective and cost saving in
improving the mental health of people with HIV [31].
This paper establishes the cost effectiveness of integrated
medical and behavioral treatment among OAWH affected by
mental health disorders.

2 Methods
2.1 Target Population
Estimates show that 70% of Americans infected with HIV
are aged 50 years or older; people of color, as well as the
lesbian, gay, bisexual, and transgender (LGBT) community
face the greater impact [32]. Primary data (n = 139) were
collected from a non-random sample of 31 HIV-infected
older White/Caucasian patients and 108 HIV-infected older
Hispanic patients. Participants were interviewed across HIV
clinics and community-based groups in New York City. Our
survey was conducted in the summer of 2018 and included
questions on socioeconomic, psychosocial, and epidemiological issues. People were screened for eligibility, which
included being 50 years of age or older, an HIV diagnosis,
and taking ART at least 12 months previous to the survey.
Funded by the HIV Intervention Science Training Program
for Underrepresented New Investigators (HISTP) [33], our
study was granted Institutional Review Board approval
for the use of human subjects in research. Informed consent was received from each participant, and participants
received assurance of confidentiality and privacy. Participants responding to the Center for Epidemiological Studies–Depression (CES-D) scale with a score of 16 or higher
were diagnosed for moderate to severe depression. QoL
scores were found using the RAND 36-Item Short Form
Health Survey (SF-36) and transformed into Short Form–6
Dimension (SF-6D) estimates to obtain utility measures
using the Sheffield licensing software [34–36], which generates a set of preference weights from the general population
to produce QALY approximations using a standard gamble
health state valuation model (Table 1).
Table 2 shows our utility scores, with a minimum of
0.459 and maximum of 0.876 (range 0.417), and with a sample mean of 0.663 (standard deviation [SD] 0.091) and 0.659
(SD 0.076) for White/Caucasian patients, and 0.665 (SD
0.095) for Hispanic patients. The utility scores depicted in
Table 2 under standard gamble health state scores were multiplied by life expectancy values for the general population at
79.8 years, and for people with HIV at 71.4 years, generating
values for effectiveness of treatment. Thus, these indexes
defined effectiveness as effMildDepress at 48.64 QALYs for
mild depression, and as effSevereDepress at 43.26 QALYs
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Table 1  Cost-effectiveness inputs (Markov)
Variable

Value

Description

tCycles
cART1

50
Number of cycles (years)
$24,881 Cost of HIV medical treatment

Distribution

References

Estimated
Log-normal distribution (mean $24,881; Gebo et al., 2010 [53]
SD $14,219; 95% CI $7621–$61,234)
Weaver et al., 2009 [55]
cMental
$45,630 Cost of having behavioral treatment
Log-normal distribution (mean
$45,630; SD $26,075; 95% CI
$13,976–$112,300)
cMental2
0
Cost of not having behavioral treatment
Estimate
pLowRiskDepress 0.588
Probability of low risk of depression
Beta distribution (mean 0.588; SD 0.06; Bhatia and Munjal, 2014 [46]
95% CI 0.468–0.703)
pHighRiskDepress 0.874
Probability of high risk of depression
Beta distribution (mean 0.874; SD 0.05; Survey, 2018
95% CI 0.761–0.954)
pDieAIDSDep
0.03
Probability of dying of HIV and depres- Beta distribution (mean 0.03; SD 0.005; Estimated
sion
95% CI 0.02–0.04)
pImprove
0.700
Probability of improving after the
Beta distribution (mean 0.700; SD 0.08; Keller et al., 1992 [53]
intervention
95% CI 0.53–0.84)
AgeStart
50
Starting age of the OAWH
Estimated
pDieAIDS
0.014
Probability of dying of HIV
CDC, 2019 [52]
eHisp
0.665
Quality of life for Hispanic subjects
Survey, 2018
eWhite
0.659
Quality of life for White/Caucasian
Survey, 2018
subjects
eSample
0.663
Quality of life for the sample
Survey, 2018
The World Bank, 2020 [38]
lifePOP
79.7
Life expectancy for the general population
lifeHIV
71.4
Life expectancy for people with HIV
Samji et al., 2013 [37]
effMildDepress
48.64
QALY for healthy OAWH
Estimated
effSevereDepress 43.26
QALY for depressed OAWH
Estimated
AgeCurrent
50 (age start) + stage
Estimated
TblDeathBackLife Table
Arias and Xu [54]
ground

OAWH older adults with HIV, QALY quality-adjusted life-year, SD standard deviation, CI confidence interval, CDC Centers for Disease Control
and Prevention

Table 2  Depression, utility, and
quality-of-life scores with eight
dimensions of health
CES-D
QoL score (O ≤ QoL ≤ 1)
Standard gamble health state score
Ordinal health state score
SF-36 Eight Dimensions of Health
Physical Functioning
Role functioning/physical
Role functioning/emotional
Energy/fatigue
Emotional well-being
Social functioning
Pain
General health

Sample
Mean (SD)

White subjects
Mean (SD)

Hispanic subjects
Mean (SD)

15.41 (6.01)
0.62 (0.11)
0.663 (0.091)
0.679 (0.114)

16.23 (4.59)
0.64 (0.09)
0.659 (0.076)
0.684 (0.109)

15.16 (6.37)
0.61 (0.11)
0.665 (0.095)
0.679 (0.116)

0.70 (0.25)
0.53 (0.44)
0.56 (0.44)
0.53 (0.21)
0.61 (0.23)
0.63 (0.29)
0.61 (0.29)
0.58 (0.24)

0.77 (0.22)
0.56 (0.43)
0.57 (0.46)
0.49 (0.16)
0.59 (0.17)
0.65 (0.28)
0.73 (0.21)
0.64 (0.20)

0.68 (0.26)
0.52 (0.44)
0.55 (0.44)
0.54 (0.23)
0.62 (0.25)
0.62 (0.30)
0.58 (0.30)
0.57 (0.25)

SD standard deviation, CES-D Center for Epidemiological Studies–Depression, QoL quality of life, SF-36
Short-Form 36
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for severe depression. Similar values were computed for Hispanic and White patients [3, 37, 38].
Our subjects included 84.2% males, and 76% lived alone.
The mean age was 59.1 years (SD 6.6). Only 17% of subjects
reported some employment status, 67.4% had some college
education, and 23.8% were undocumented immigrants. Our
participants experienced high levels of ART adherence, i.e.
95.2% (standard error [SE] 1.9%) in the sample, 96.6% (SE
3.4%) in White subjects, and 94.8% (SE 2.2%) in Hispanic
subjects. The proportion of viral suppression was 95.2% (SE
1.9%) in the sample, 100% for White/Caucasian subjects,
and 93.8% (SE 2.4%) for Hispanic subjects; OAWH achieved
ART adherence, with the corresponding viral load and CD4
T cells at clinically acceptable levels.

2.2 Decision Model
The Markov model was based on a cohort simulation size
of 1, which is split into fractions as it spreads through the
model cycle-by-cycle. We obtained a weighted average of
all patient pathways based on the assigned probabilities,
with costs and utilities accumulating along the path via the
weighted average calculations to obtain the average cost and
effectiveness per patient. We estimated the cumulative cost
and effectiveness of behavioral care for OAWH over a finite
time frame using singular health states.
Figure 1 shows the state transition diagram, which was the
base upon which to build state rewards using Markov cycle
trees in TreeAge Pro [39]. We probed the relative health outcomes of two strategies: medical care only (medical) compared with medical plus behavioral care (medical + behavioral), assuming integrated systems where doctors referred
patients to suitable mental health services, with follow-up
over time. Integrated care for OAWH provides ART concurrent with mental health treatment to address several forms
of depression and substance use, conditions that were highly
prevalent in our sample. This combined intervention can be
delivered in a single facility, in multiple places, or can be
facilitated by a case manager or social worker. In each setting, we need to consider cost-effectiveness issues as well as
potential fragmentation and deficiencies in the coordination
of services [26].
We simulated the progression of depression and cumulative deaths for 50 years to follow our cohort throughout their lifetime horizon, using mutually exclusive and
exhaustive health states, with movements across health
states determined by transition probabilities. Our model
included cohort analysis with half-cycle corrections to
reduce the impact of overestimates [40]. Every cycle
carries the costs and effectiveness, with a probability of
developing ‘no to mild depression’, meaning that OAWH
adhere to ART, stay virally suppressed throughout the
cycles, and show, at most, mild depression or substance

Fig. 1  State transition diagram of strategies: the circles represent the
health states and the arrows represent the transition between different
health states. Individuals can stay in their health states as well as transit back and forth between health states. Death is the terminal node
and bears neither cost nor efectiveness rewards

use. The risk of feeling ‘moderate to severe depression’
represents a person who may adhere to ART, is virally
suppressed, and experiences at least moderate depression
being referred and followed-up to behavioral care. The
criteria for depression was established using the CES-D20 survey, in which a participant with a score of 16 points
or more is considered moderately to severely depressed
[41, 42]. The probability of ‘dead’ in all health states was
caused by AIDS or severe mental health conditions and
mortality caused by factors different from those under
study [43, 44].
Figure 2 depicts the full decision analytic model. At
cycle 0, all individuals enjoy relatively good QoL (no to
mild depression) and remain in good health (StaysMild),
are diagnosed with depression (depressive), or can die from
AIDS-related conditions (DieAIDS). OAWH in the moderate to severe depression state experience low QoL but are
referred to behavioral care, then improve and return to the
no to mild depression state. If mental health treatment fails,
the OAWH stays depressed (StayDep) and the likelihood
of early death increases (DieAIDS + Depress). Background
death occurs in all health states. The cohort moves between
health states as time progresses, and then splits among states
before each cycle is given a probability. The transition subtrees are associated with health states occurring within a
cycle until the terminal node is reached; the cohort then
returns to a health state for the next cycle via the jump state.
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Fig. 2  Decision analytic model (Markov tree diagram). TreeAge model for decision analysis with two strategies, three health states, and transition probabilities, representing events within a cycle rather than all scenarios over the entire time horizon

The strategies of both the medical and medical + behavioral
cohorts follow the same pattern.

2.3 Cost, Effectiveness, and Probabilities
Table 1 describes the economic evaluation inputs used in the
Markov model health states [45]. We compared two groups
of OAWH, one with a low risk of depression of 58.8%
[46] and those who experienced a high risk of depression
of 87.4%. Given the probability of improving (pImprove)
from the intervention, we argue that an initial low level of
moderate or severe depression among OAWH maximizes
health and produces the largest number of QALYs for the
expenditure. Our goal is to compute cost and effectiveness
derived from mental health care. The rate of dying from

AIDS-related conditions (pDieAIDS) in the no to mild
depression group [47–50] was 1.42%, computed from people with HIV who died in 2017 divided by the estimated
prevalence [51]. Because OAWH are at higher risk from
comorbidities and other factors [52], we reasonably assumed
the likelihood of dying from AIDS-related and depressionrelated conditions (pDieAIDSDep) while being in the moderate to severe depression state was 3%. Keller et al. [53]
suggested that after consistent and supervised mental health
treatment, at most 70% of patients recover from depression
within the year; this value served as the probability of recovering from depression during the cycle (pImprove). Background mortality was built using the 2017 US Life Tables
from the Centers for Disease Control and Prevention [54] for
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a period of 50 years (ages 50–100 years) to account for the
lifetime horizon of our cohort.
The cost-effectiveness analysis (CEA) used a healthcare perspective because the cost of reducing mental
health disorders is carried by a third-party or by patients
[55]. There is limited information regarding the treatment
cost, and data are often retrieved from the current literature. The average annual cost of medical treatment for
people with HIV (cART1 in the no to mild depression
state) was $24,881 per year in 2006 prices inflated to
2019, based on a large-scale purchaser of services providing large discounts [56]. These values included the per
unit cost of clinic visits (inpatient, outpatient, and emergency) multiplied by its frequency, as well as blood tests,
HIV medications, and opportunistic infection drugs over
1 year [57]. Weaver et al. [58] used a health sector budget
view to determine the cost of HIV treatment with integrated care for chronic mental illness and substance abuse
disorders among HIV-infected individuals (cMental1 for
the moderate to severe depression state). The cost was
$45,630 per year in 2009 prices inflated to 2019, comprising medical, mental health, and substance abuse visits
to inpatient, outpatient, and correctional facilities, and
cost of medications among eight types of services, and
used Medicare payments for monetary values; this calculation excluded patient and family costs. The willingness
to pay (WTP) or “the basis of the Value of a Statistical
Life and other measures used for calculating the economic
value of morbidity and mortality improvements” [59]
was computed using a scalar for the 2018 gross domestic
product and was set at $50,000 per QALY [60–62]. We
inflated the cost of HIV and mental health treatment to
2019 US dollar values to account for inflation, based on
the Consumer Price Index capturing changes in the prices
of goods and services purchased by urban households, not
Table 3  Cost-effectiveness
rankings

Strategy
(a) Deterministic
Medical
Medical + behavioral
(b) Probabilistic
Medical
Medical + behavioral

seasonally adjusted [63]. We applied a 3% discount rate
for cost and effectiveness occurring in the future.

3 Results
Based on a Markov analysis, the medical + behavioral strategy is cost effective compared with medical-only treatment,
with a WTP at $50,000 per QALY. Table 3a reports the
cost-effectiveness rankings for the two strategies, with an
incremental cost of $518,971, an incremental effectiveness of 38.8 QALYs, and an incremental cost-effectiveness
ratio (ICER) of $13,380 per QALY. As originally expected,
the net monetary benefits (NMBs) are higher for the medical + behavioral intervention compared with the medicalonly intervention.

3.1 Survivorship and Cumulative Death
The Markov probability analysis graph shown in Fig. 3
shows that as the cohort moves across the cycles, the survival curve for no to mild depression lies above the moderate to severe depression curve. The initial depression rate
was fairly high in our sample, but our model assumes that
moderate or severe depression was addressed in a timely
and successful manner by targeted referrals to mental health
services. The whole cohort starts at stage 0 of the Markov
simulation but splits in the transition subtrees, where 39.6%
of the cohort show signs of no to mild depression but 58.5%
experience moderate to severe depression and 1.9% die
from causes unrelated to HIV/AIDS or depression in year
1. We presumed that OAWH with major depression were
referred to behavioral care, with a 70% chance of improving within the first year. In year 2, because 70% of those
patients recovered from depression and returned to the no

Cost

Δ Cost

Effa

Δ Effb,c

ICERc

NMB

$243,164
$759,615

$516,452

1080.8
1119.6

38.8

$13,316

$53,796,665
$55,219,527

$280,052
$886,145

$606,093

1080.8
1107.2

26.4

$22,946

$53,759,777
$54,474,362

Δ Cost represents the difference between the less expensive intervention (medical care only) and the more
expensive intervention (medical + behavioral care)
Δ Effectiveness represents the difference in effectiveness between our two strategies, ICER represents the
ratio of incremental cost divided by the incremental effectiveness, NMB represents the monetary value of
a program given the WTP, Eff effectiveness, ICER incremental cost-effectiveness ratio, NMB net monetary
benefit, QALYs quality-adjusted life-years, WTP willingness to pay

a

b
c

Measured in QALYs
Incremental effectiveness
Measured in US dollars per QALY
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Fig. 3  Markov probability
analysis (medical + behavioral
strategy). The survival curve
for no to mild depression lies
above the moderate to severe
depression curve. Cumulative
mortality rises throughout the
lifetime of the simulation

to mild depression state, 56.4% were now in the no to mild
depression state, 38.9% were in the moderate to severe
depression state, and the cumulative death rate rises to 4.7%.
After 25 cycles, only 43.3% of the cohort are still alive,
being the proportion of individuals with no to mild depression higher than those in the moderate to severe depression
cohort; the cumulative death rate is 56.7%. By the end of
the 50th cycle, < 0.7% of the initial cohort remain alive. The
medical + behavioral cumulative cost was $762,135 and the
cumulative effectiveness was 1119.6 QALYs. Because our
initial depression rate was high, and in the absence of behavioral care, a sizable share of the subjects would have transited to the depressive state and died due to AIDS-related or
depression-related conditions. The provision of integrated
treatment allowed some to recover within 1 year and go back
to a mild depression state, however some patients relapsed.

3.2 Sensitivity Analysis: Deterministic (DSA)
and Probabilistic (PSA)
As there are several sources of parameter uncertainty, we ran
sensitivity analyses with 1000 iterations to fathom how variations in the input parameters (cost, effectiveness, or probabilities) impacted the results (ICER or NMB). Sensitivity
analyses accounted for uncertainty in estimating the parameter and around the model’s assumptions. We choose a range

of probability values while keeping the remainder of the
variables constant. We varied the baseline probability and
utility estimate values to probe whether the results changed
given the parameters [64, 65], addressing the unpredictability of health states [66, 67]. These values were compared
with the outputs, considering a WTP of $50,000 per QALY.

3.3 DSA
The one-way sensitivity analysis illustrated in Fig. 4 shows
the positive relationship between pImprove and NMB
(monetary value of the intervention given the WTP for a
unit of benefit) for those who received mental health treatment, measuring the efficacy of the medical + behavioral
strategy. Likewise, when pImprove increases, the ICER,
or the cost of an additional unit of perfect health (dollar
value of QALY), tends to decline. For pDieAIDSDep, both
the monetary value of the intervention and the per QALY
cost decline. Figure 5 illustrates that as QALYs increase,
the NMBs rise and the medical-only strategy is only cost
effective below 41.45 QALYs, but, above that point, the
medical + behavioral strategy becomes cost effective, confirming that our utility values are within the right boundaries. These graphs also indicate that as the number of
QALYs increase for OAWH who are severely depressed,
the medical + behavioral strategy has limited benefits and
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Fig. 4  One-way sensitivity analysis—pImprove and pDieAIDSDep
(WTP = $50,000). pImprove is the share of OAWH who recover from
depression due to mental health care, and pDieAIDSDep is the share
of OAWH who die due to HIV/AIDS and depression-related condi-

tions, excluding background mortality. WTP willingness to pay,
OAWH older adults with HIV, ICER incremental cost-effectiveness
ratio, NMB net monetary benefit

stops being cost effective up to 61.8 QALYs; however,
after this point, the medical-only strategy becomes cost
effective. The tornado diagram shown in Fig. 6 specifies
that changes in HIV/AIDS and depression-related mortality have the greatest effect on outcome, while variations
in the cost of HIV care have relatively small effects on
outcome.

transformed the parameters into distributions to confirm, or
not, our base case [55, 68–71]. In the original model, we
defined the medical + behavioral strategy as cost effective,
however this result provides a moderate but not overwhelming confidence because the result was based on a predetermined parameter. Our PSA output was similar to the base
case and confirms that the medical + behavioral strategy is
cost effective. Table 3b shows the cost-effectiveness rankings, with results confirming those of the original model,
with an ICER higher in the probabilistic analysis ($22,946)
compared with the base model ($13,315). Figure 7 introduced the cost-effectiveness acceptability curve (CEAC)
to establish that at the bottom of the WTP threshold range
(< $29,000 per QALY), the medical-only strategy has the
highest probability of being cost effective. The CEAC
indicates that for a WTP > $29,000 per QALY, the medical + behavioral strategy has the highest probability of being
cost effective compared with the alternative. When the WTP

3.4 PSA
We conducted a PSA to inspect the effects of several input
variables on outputs at the same time. A beta distribution
was used for probabilities, which are bounded between 0
and 1, while a log-normal distribution was used for the costs
where the support of the distribution is from zero to infinity. We used a Monte Carlo simulation technique with 1000
samples and repeated the process several times to ensure that
the values were stable enough. From the original model, we
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Fig. 5  One-way sensitivity analysis—effMildDepress and effSevereDepress (WTP = $50,000). Proxies for treatment effectiveness
describing the utility of being mildly depressed (effMildDepress) and

severely depressed (effSevereDepress), both measured in QALYs.
WTP willingness to pay, QALYs quality-adjusted life-years, NMB net
monetary benefit, ICER incremental cost-effectiveness ratio

was $50,000, the medical + behavioral strategy was chosen
68.8% of the time, but at $100,000, the likelihood of selecting the medical + behavioral strategy would be 81.7%. Figure 8 introduces the incremental cost-effectiveness scatter
plot displaying the likelihood that our medical + behavioral
treatment could be chosen, with the share of points within
the scatter plot falling to the east and south of the WTP line,
with the slope passing through the origin [72]. We confirmed
that 68.8% of the points lie to the right of the WTP ray,
thus make our strategy a superior choice compared with the
medical-only strategy.

4 Discussion
HIV is multifactorial and requires clinically sound
approaches concomitant with innovative mental health and
social and legal services to produce cost-effective outcomes.
OAWH taking ART are vulnerable to mental health disorders and our sample reported a group of aging people with
HIV experiencing an unusually high level of mental health
illness, with a substantial share who did not seek treatment.
An integrated system is instrumental to significantly reduce
the effect of the epidemic and achieve better QoL [73]; this
is important because our sample showed high depression
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Fig. 6  Tornado diagram—ICER. Medical + behavioral vs. medical (WTP = $50,000). This graph shows how changes in each input variable
affect the outcome, and are arranged in decreasing width order. ICER incremental cost-effectiveness ratio, WTP willingness to pay

levels concurrent with substance use and risky sexual
behaviors, which is consistent with the literature [74–76].
Depression is a common and usually misdiagnosed medical
challenge affecting the lifecycle of OAWH [77–79]; however, unfortunately, OAWH and older Hispanic patients with
HIV underutilize mental health services [80, 81]. Moreover,
social isolation and loneliness are associated with mental
health disorders and predict poor health and an increased
likelihood of premature death [82–84]. Psychosocial conditions are both a medical dilemma and an economic conundrum affecting OAWH, and, without family and community support, behavioral illnesses add $7 billion to Medicare
costs as a result of longer stays in hospitals [85]. Thus, costeffectiveness and cost-saving studies are paramount to better
understand the resource allocation of clinical interventions.

We proxied psychosocial factors to predict poor health
and survival rates in our sample of OAWH [86]. We recommended mental health integrated to state-of-the-art medical
treatment as a cost-effective approach. Although people with
HIV/AIDS under ART have a low risk of dying as a result
of the infection [87], there is evidence that death rates are
higher among people with HIV when compared with the
general population [48, 88, 89]. In our model, cumulative
mortality was lower for the medical + behavioral strategy
compared with the medical-only strategy, suggesting that
an integrated system that efficaciously links HIV patients
with assorted mental health services produces the largest
number of QALYs for the outlay [90]. It is important to
recognize that psychological disorders represent a syndemic
of behavioral health issues that include depression, loneliness, trauma derived from having HIV, and substance use
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Fig. 7  CEAC (WTP = $50,000), which was based on 1000 iterations or samples to summarize uncertainty of the estimates. CEAC cost-effectiveness acceptability curve, WTP willingness to pay

[77, 91, 92]. Thus, focusing on these problems in isolation
will unlikely resolve contributing factors; for instance, treating depression without acting to reduce social isolation and
loneliness that may exacerbate, if not be the root cause of,
this condition [93]. Pharmacological treatment of behavioral health problems is the most cost effective, if combined
with other therapeutic modalities [94, 95]. Thus, outpatient
clinics, community-based programs, and individual face-toface psychotherapy combined with other remedies are at the
high-end regarding effectiveness and cost. These costs can
be reduced with high efficacy through the use of telemedicine or group therapy [96], with the caveat that technology
can also be a source of health disparities. Small and closed

groups based on positive psychology principles with elements of psychoeducation and therapeutic effects of group
participation have been proven to be effective [97]. An adaptation of the MacArthur Project, with respect to intervention for OAWH, is a low-cost and scalable social support
program that, in combination with treatment as usual, halved
depressive symptom scores over a 6-month period [98].
These interventions reduce social isolation and promote
social interaction through group therapy or weekly phone
calls from a care manager. The use of mobile phone technologies offers additional low-cost and high efficacy options
for reducing mental health problems in OAWH in resourcepoor areas in Latin America and sub-Saharan Africa [99,
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Fig. 8  Scatter plot of incremental cost-effectiveness: medical + behavioral versus medical. This scatter plot identifies the probability that the new treatment is cost effective, where the vertical axis
represents the incremental cost, the horizontal axis is the incremental

effectiveness, and the ellipses denote 90% and 95% confidence intervals. More than 68.8% of the points lie to the right of the WTP ray,
thus make our strategy a superior choice compared with ‘medical’
only. WTP willingness to pay

100], and was particularly effective in reducing social isolation among people with HIV in rural areas. In addition, the
trauma-informed peer support for people living with HIV
can be cost effective [101]. Thus, mental health interventions
that are able to address the multifaceted causes of psychological distress among OAWH can be highly effective, but
are not always high-cost programs.

The lack of evidence-based cost studies for the gradient of HIV and mental health interventions is a limitation
of our study. Furthermore, non-probability samples do not
contain all members of a population and carry lower levels
of generalization. Time is a crucial parameter of Markov
models that facilitates the analysis of chronic diseases, thus
future states depend only on the current states and not on
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the path followed in the past [102]. This could be restrictive
for specific diseases and models with many states. Cohort
simulations assume an homogeneous population with constant risk throughout the time horizon. CEAs use refined
statistical and standardized procedures and serves as a guide
for resource allocation [103]. Markov models are simple and
easy to understand for a broader audience but can be contentious because they assign implicit and explicit monetary
values on human life, therefore decision makers can use this
knowledge to control expenses. CEAs have been extensively
used in economic evaluations but seldom discuss issues of
fairness and equity. Our findings cannot serve as a substitute
for value judgments.

5 Conclusions
We determined that an integrated system (medical + behavioral) is cost effective to improve QoL among OAWH. We
produced a computer-generated progression of mental health
and death to synthesize information using a Markov model
based on simple mathematical constructions [104]. As
simulated in our model, assuming effective identification
of mental health disorders and proper referral to care is key
to producing better health outcomes. Our findings inform
how resource allocation can improve health outcomes based
on our sample results. Policy makers need to prioritize the
share of people virally suppressed with the addition of mental health care in the midst of the ‘graying’ of the epidemic.
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